These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 335364)

  • 1. [Clinical pharmacology of furosemide].
    Prandota J; Witkowska M
    Pol Tyg Lek; 1977 Sep; 32(39):1529-32. PubMed ID: 335364
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of biliary excretion in the hepatotoxicity of furosemide in the mouse.
    Spitznagle LA; Wirth PJ; Boobis SW; Thorgeirsson SS; Nelson WL
    Toxicol Appl Pharmacol; 1977 Feb; 39(2):283-94. PubMed ID: 847756
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparative diuretic and tissue distribution study of bumetanide and furosemide in the dog.
    Cohen MR; Hinsch E; Vergona R; Ryan J; Kolis SJ; Schwartz MA
    J Pharmacol Exp Ther; 1976 Jun; 197(3):697-702. PubMed ID: 932999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative determination of furosemide in plasma, plasma water, urine and ascites fluid by high-performance liquid chromatography.
    Uchino K; Isozaki S; Saitoh Y; Nakagawa F; Tamura Z; Tanaka N
    J Chromatogr; 1984 Jun; 308():241-9. PubMed ID: 6746817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between tubular secretion of furosemide and its saluretic effect.
    Odlind B
    J Pharmacol Exp Ther; 1979 Mar; 208(3):515-21. PubMed ID: 430368
    [No Abstract]   [Full Text] [Related]  

  • 6. Disposition of furosemide in functionally hepatectomized dogs.
    Verbeeck RK; Gerkens JF; Wilkinson GR; Branch RA
    J Pharmacol Exp Ther; 1981 Mar; 216(3):479-83. PubMed ID: 7205627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Furosemide pharmacokinetics and its relevance to ototoxicity.
    Kshirsagar NA; Dahanukar SA; Shah BP; Vora KK; Karandikar SM; Acharya VN; Sheth UK
    J Postgrad Med; 1978 Jan; 24(1):20-3. PubMed ID: 731608
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatic and renal metallothionein induction in the rat and mouse after treatment with furosemide.
    Wormser U; BenZakine S; Nyska A
    Biochem Int; 1991 Jan; 23(2):419-28. PubMed ID: 1859441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal and hepatic necrosis after metabolic activation of 2-substituted furans and thiophenes, including furosemide and cephaloridine.
    McMurtry RJ; Mitchell JR
    Toxicol Appl Pharmacol; 1977 Nov; 42(2):285-300. PubMed ID: 595008
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacokinetics of 35S-furosemide in experimental kidney failure in the rat].
    Mansouri M; Legheand J; Sassard J
    J Pharmacol; 1984; 15(1):79-86. PubMed ID: 6717029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tissue respiration as influenced by furosemide and hydrochlorothiazide].
    Petruch F; Burck HC
    Naunyn Schmiedebergs Arch Pharmakol; 1970; 266(4):423-4. PubMed ID: 4253848
    [No Abstract]   [Full Text] [Related]  

  • 12. [Levels of plasma proteins in patients with ene stage renal failure treated with peritoneal dialysis with an addition of furosemide to dialysis fluid].
    Grzegorzewska A; Krzymański M; Antoniewicz K
    Pol Tyg Lek; 1994 Feb 7-14; 49(6-7):137-40. PubMed ID: 8090666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of experimental azotemia on renal clearance of furosemide in the dog.
    Rose HJ; Pruitt AW; McNay JL
    J Pharmacol Exp Ther; 1976 Jan; 196(1):238-47. PubMed ID: 1246013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of furosemide in children with nephrotic syndrome.
    González-Martín G; Bravo I; Ibarra N; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1983 Dec; 21(12):598-601. PubMed ID: 6668097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Furosemide interference in newer free thyroxine assays.
    Christofides ND
    Clin Chem; 1999 Aug; 45(8 Pt 1):1315. PubMed ID: 10430826
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic effects of furosemide in patients with impaired renal function.
    Traeger A; Stein G; Sperschneider H; Keil E
    Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):481-6. PubMed ID: 6500766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacokinetics of frusemide.
    Cutler RE; Blair AD
    Clin Pharmacokinet; 1979; 4(4):279-96. PubMed ID: 385209
    [No Abstract]   [Full Text] [Related]  

  • 18. [Pediatric pharmacology].
    Guignard JP
    Rev Med Suisse Romande; 1980 Mar; 100(3):227-35. PubMed ID: 7394430
    [No Abstract]   [Full Text] [Related]  

  • 19. Role of binding in distribution of furosemide: where is nonrenal clearance?
    Branch RA
    Fed Proc; 1983 Apr; 42(6):1699-702. PubMed ID: 6832389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic clearance of furosemide in the rat.
    Wallin JD; Ryals P; Kaplowitz N
    J Pharmacol Exp Ther; 1977 Jan; 200(1):52-7. PubMed ID: 833762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.